🎥 New Special Report! 🎥 We’re excited to present a special 5-part series on Embracing New Therapies in Schizophrenia Management, with insights from leading subject matter experts Rishi Kakar, MD, of Segal Trials, Andrew Cutler, MD, Neuroscience Education Institute, and moderator Sam Clark, MD PhD, of Terran Biosciences. In this series, we dive deep into the groundbreaking FDA-approved schizophrenia treatment, xanomeline and trospium chloride capsules (Cobenfiy; Bristol Myers Squibb), and its novel mechanism of action targeting muscarinic receptors instead of traditional dopamine pathways. The series highlights key clinical trial data, symptom management, and how these new therapies could revolutionize treatment for patients who haven't fully responded to traditional antipsychotics. Watch and learn how these advancements may shape the future of schizophrenia care, improve patient outcomes, and address unmet needs in managing this complex condition. In the segment below, the experts discuss the application of clinical trial data to real-world settings. Use the link for the full series! https://lnkd.in/eDvyx_9S #Schizophrenia #Neuropsychiatry #MentalHealth #Psychiatry
HCPLive’s Post
More Relevant Posts
-
https://lnkd.in/g5qk52NU Article title: Comparison of two questionnaires (PDQ-39 and SEIQoL) for assessment of the quality of life in idiopathic Parkinson’s disease Author(s): Lena Waldvogel; Ketevan Toloraia; Peter Fuhr; Ute Gschwandtner* Journal: Annals of Psychiatry and Treatment Journal ISSN: 2640-8031 Abstract: Parkinson’s disease is a neurodegenerative disease of the central nervous system that begins insidiously and progresses over time with a loss of nerve cells in certain brain regions. People with chronic diseases often experience a change in their quality of life. For patients, relatives, and the whole community, a reduced quality of life can pose a significant burden. Therefore, it is imperative to reduce socioeconomic costs to preserve high health quality in patients with neurodegenerative disorders. Parkinson’s disease can cause people to have difficulty performing daily activities such as working or shopping. It is not uncommon for social interaction to be impaired, as patients sometimes struggle to participate in social life due to their symptomatology. The quality of life of Parkinson’s disease patients can be measured in different ways. A distinction can be made between Health-related Quality of Life and Individualised Quality of Life. Several questionnaires and screening tools are investigating the Quality of Life in patients with Parkinson’s disease. However, their validity and practicability are often not extensively analyzed. #ParkinsonsDisease #PDQ39 #SEIQoL #QualityOfLife #Neurodegeneration #BiologicalPsychiatry #Psychopharmacotherapy #PsychologicalMedicine #ForensicPsychiatry #SocialPsychiatry #Sociotherapy #PTSD #Peertechz #PeertechzPublications #ChildAndAdolescentPsychiatry #AddictionPsychiatry #MoodDisorders #Nosography #Schizophrenia
To view or add a comment, sign in
-
https://lnkd.in/gVNV7Yuv Large-scale study links ketamine to lower risk of suicidal ideation in depression patients Ketamine significantly reduces suicidal ideation in MDD patients: A large-scale study found that patients with recurrent major depressive disorder (MDD) who were prescribed ketamine had a lower risk of developing suicidal thoughts compared to those prescribed traditional antidepressants, with effects lasting up to 270 days. Greater effect in certain demographics: The reduction in suicidal ideation was more pronounced in individuals over the age of 24 and in white patients, while no significant difference was observed for those under 24 or for Black patients, possibly due to smaller sample sizes. Limitations and future research: As a retrospective study, it only shows an association, not causality, and further research is needed to explore dosage, duration, and how ketamine compares with other treatments for depression, such as therapy or electroconvulsive therapy. #PsychedelicMedicine #PsychedelicTherapy #KetamineResearch #DepressionTreatment #MentalHealth #SuicidalIdeation #MajorDepressiveDisorder #Antidepressants #MentalHealthMatters #Psychiatry #KetamineEffect #MDD #SuicidePrevention #LongTermEffects #MentalHealthCare #ClinicalResearch #KetamineStudy #Neuroscience #PublicHealth
To view or add a comment, sign in
-
Long noncoding RNAs emerge as promising biomarkers for mood disorders. New review highlights potential of blood-based RNA molecules for diagnosis and treatment of depression and bipolar disorder. In a groundbreaking peer-reviewed review article, researchers have uncovered compelling evidence that long noncoding RNAs - molecules once dismissed as "junk DNA" - may hold the key to revolutionizing how we diagnose and treat mood disorders. The study, published in the journal Genomic Psychiatry (Genomic Press, New York), reveals that these RNA molecules circulating in blood samples could serve as powerful biomarkers for conditions like major depression and bipolar disorder, potentially leading to more accurate diagnoses and personalized treatments. For more information, click here for the full, open-access PDF: https://lnkd.in/dCnX5gaT The EurekAlert! news release can be found here: https://lnkd.in/dGV_5efy #UAB #YogeshDwivedi #MentalHealth #MentalHealthMatters #LncRNABiomarkers #MoodDisorderResearch #DepressionBiology #BipolarBiomarkers #PsychiatricGenomics #EpigeneticsAndMentalHealth #CirculatingLncRNA #PersonalizedPsychiatry #BrainEpigenetics #MolecularPsychiatry #PrecisionMentalHealth #BiomarkerDiscovery #DepressionDiagnosis #BipolarTreatment #NoncodingRNA #PsychiatricBiomarkers #MentalHealthGenomics #RNABiomarkers #BloodBasedBiomarkers #FutureOfPsychiatry
To view or add a comment, sign in
-
Researchers at Dalhousie University, led by Nelofar Kureshi, have explored the connection between traumatic brain injury (TBI) and the development of new-onset psychiatric disorders (NPDs). Using a dataset of 3,453 TBI patients and 13,112 controls from a provincial trauma registry, they applied latent class analysis to uncover distinct phenotypes within the TBI population. The results showed that TBI patients are significantly more likely to develop NPDs compared to non-TBI individuals, with odds ratios of 2.78 for those without pre-injury psychiatric history and 2.36 for those with prior psychiatric conditions. Eight different phenotypes were identified, each showing varying risks for NPD development, influenced by factors like age, injury severity, length of hospital stay, and discharge destination. For example, older adults requiring extended recovery and supportive care showed a 53% higher risk of developing NPDs compared to younger individuals with shorter recovery times. This research emphasizes the need for tailored psychiatric care, particularly early intervention based on individual risk profiles. By identifying specific patient clusters, this study offers a framework for improving mental health outcomes in TBI patients through targeted, phenotype-driven care strategies. The findings highlight the importance of integrating psychiatric risk assessments into TBI patient care, particularly at discharge, to better manage long-term psychiatric effects and improve patient recovery. #TBI #Psychiatry #Neuroscience #MentalHealth #HealthcareInnovation #PublicHealth #TraumaCare
To view or add a comment, sign in
-
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. In our new podcast, the co-author of a guest editorial, “Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry,” Hubertus Himmerich, MD, reviews the implications of GLP-1 drugs for psychiatry and healthcare globally. 🎧 Listen to podcast: https://lnkd.in/dk5nxTDS 📰 Read the article: https://lnkd.in/d4jUFPJv #psychopharmacology #GLP1 #semaglutide #ozempic #wegovy #diabetes #obesity #weightloss #psychiatry #depression #bingeeating #antipsychotics
To view or add a comment, sign in
-
*SPRAVATO AS MONOTHERAPY FOR TRD!* Patients on Spravato for treatment resistant depression may soon no longer need to take an oral antidepressant…. My clinical experience all these years has been validated by this research poster presented Psych Congress 2 weeks ago Here are highlights from the poster: Esketamine Nasal Spray for Treatment-Resistant Depression -Study Context: A randomized, double-blind study presented at Psych Congress 2024 examined esketamine nasal spray monotherapy in adults with treatment-resistant depression. -Participant Criteria: Adults with major depressive disorder (MDD) with no psychotic features, high depressive symptom scores, and nonresponse to ≥2 oral antidepressants (OADs) were included. -Study Design: After a 2-week OAD-free period, participants (n=378) were randomized (2:1:1) to placebo or ESK doses (56mg/84mg) twice weekly for 4 weeks. -Key Findings: -Primary Endpoint: Mean change in MADRS score at day 28 was significantly better for ESK vs. placebo (56mg: −5.1, 84mg: −6.8; P< 0.001). -Secondary Endpoint: At day 2, MADRS score changes for ESK (56mg: p=0.004; 84mg: P=0.006) also outperformed placebo. -Safety Profile: Common adverse events (≥10%) included nausea, dissociation, dizziness, and headache. No new safety concerns emerged. The full manuscript has been submitted to JAMA, Journal of the American Medical Association Psychiatry and if accepted and published, will be out in 2025. Check out this article to learn more: https://lnkd.in/eEq3w5x9 • #PsychCongress2024 • #Esketamine • #TreatmentResistantDepression • #MentalHealthResearch • #Psychiatry • #ClinicalStudy • #DepressionTreatment • #EsketamineEfficacy • #MentalHealthAwareness • #InnovativeTherapies • #DepressionResearch • #Psychopharmacology
To view or add a comment, sign in
-
📰 A new study suggests #TMS as a treatment for #Depression, is likely to be more beneficial than trying a new antidepressant medication 💊 A recent study published in the #AmericanJournalofPsychiatry highlights a significant advancement in depression treatment: Transcranial Magnetic Stimulation (TMS) therapy may be more effective than trying another course of antidepressant medications, especially after multiple failed attempts. With nearly 300 million people worldwide battling severe depression, this finding offers a promising alternative for those who haven't found relief with traditional treatments. The study, co-authored by Dr. Iris van Oostrom from neurocare Clinics Nederland , found that patients receiving TMS experienced significantly greater reductions in depression symptoms compared to those trialing another course of antidepressant. "After 8 weeks of treatment, we found that the group that received TMS had significantly lower depression rates than the group that received medication during these 8 weeks," says Dr. van Oostrom. As TMS gains recognition in depression treatment guidelines around the world, this non-invasive therapy is becoming a beacon of hope, providing patients with more effective and personalized treatment options. 🔗 Read the full article in the link in the comments. #neurocare #neurocaregroup #bestpractice #psychiatry #psychology #antidepressants #rtms #tms #neurostimulation #neuromodulation #magneticstimulation #depressiontreatment #clinicalcare #healthcareinnovation
To view or add a comment, sign in
-
The glucagon-like peptide 1 (GLP-1)–based diabetes and obesity drug semaglutide, with trade names Ozempic and Wegovy, will become the second best-selling drug in 2024, with estimated worldwide Ozempic sales of US ~$16 billion. In our new podcast, the co-author of a guest editorial, “Glucagon-Like Peptide 1 Receptor Agonists in Psychiatry,” Hubertus Himmerich, MD, reviews the implications of GLP-1 drugs for psychiatry and healthcare globally. 🎧 Listen to podcast: https://lnkd.in/dk5nxTDS 📰 Read the article: https://lnkd.in/d4jUFPJv #psychopharmacology #GLP1 #semaglutide #ozempic #wegovy #diabetes #obesity #weightloss #psychiatry #depression #bingeeating #antipsychotics
To view or add a comment, sign in
-
A cancer diagnosis is life altering and frequently associated with both acute and long-lasting psychosocial and behavioral distress for patients. The impact of a diffuse glioblastoma multiforme diagnosis on mental health is an important aspect of the patient experience with their disease. This needs to be understood by neurosurgeons so these concerns can be appropriately addressed in a timely fashion and integrated into the multidisciplinary care of neuro-oncology patients. The relatively grave prognosis, the morbidity associated with treatment, and the constant threat of developing a new neurological deficit all can negatively affect a patient’s mental ability to cope and ultimately manifest in mental health disorders like anxiety and depression. Given the strong correlation between quality of life and patient mental well being, there is a considerable need for early recognition and treatment of these behavioral health disorders to optimize everyday functioning for patients. Credit @braintumor.org @pmc #gbm #gbmawareness #glioblastomamultiforme #glioblastomaawareness #braintumorsurvivor #BrainHealth #Braintumor #braintumorawareness #neurosciences #neurosurgeon #cancerawareness #cancer #psychiatry #psychiatristsofinstagram #psychooncology #memories #remembering #therapy #majormissing #neverforgotten
To view or add a comment, sign in
-
AUSTRALIA MAKES GLOBAL HISTORY IN PSYCHEDELIC MEDICINE. The Swedish Network for Psychedelic Science invites Mind Medicine Australia to give an international webinar on the process of implementing psychedelic medicine in the Australian Health care System: "Changing Minds, Saving Lives: Developing the Ecosystem to Bridge the Translation of Psychedelic Therapies from Research into Clinical Practice" Over the last 5 years Australia has gone from being way behind the rest of the world to now being one of the leaders in the translation of these therapies so that they can be accessed through the medical system. Mind Medicine Australia’s co-Founder, Tania de Jong and Psychiatrist and Authorised Prescriber Dr Ted Cassidy will present this international webinar. Join the webinar on 27 May: https://buff.ly/3QO0V6P #MentalHealthAwareness #trauma #ptsd #MDMA #addiction #depression #psilocybin #psychiatry #psychology #psychedelictherapy #psychedelics #medicine #innovation #neuroscience #event #webinar
To view or add a comment, sign in
3,830 followers
Care Coordinator at NCH
1moLove this